Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03872596
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : June 17, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:

This is a two-part trial.

The primary objective of Part A is to estimate the ratio of geometric means of pharmacokinetic (PK) parameters and their within-subject variability for the 300mg quetiapine tablet formulation A and the 300mg quetiapine tablet formulation B compared to 300mg Seroquel.

The primary objective of Part B is to estimate the ratio of geometric means of PK parameters and their within-subject variability for the selected tablet formulation from Part A of 25mg quetiapine compared to 25mg Seroquel.


Condition or disease Intervention/treatment Phase
Bipolar Disorder Schizophrenia Drug: Seroquel IR 300mg Drug: Seroquel IR 25mg Drug: Quetiapine Formulation A 300mg Drug: Quetiapine Formulation B 300mg Drug: Quetiapine Formulation 25mg Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This is a two-part, crossover study. In Part A, participants will be randomized into one of three treatment sequences, each receiving Seroquel immediate release (IR) 300mg, Quetiapine Formulation A 300mg and Quetiapine Formulation B 300mg. In Part B, participants will be randomized into one of two treatment sequences, each receiving Seroquel IR 25mg and Quetiapine 25mg, the formulation of which will be established in Part A.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, 2-Part, Open-Label, Randomized, Crossover Pilot Trial to Assess the Relative Bioavailability of Quetiapine Versus Seroquel® 300-mg Oral Tablets in Subjects With Schizophrenia or Bipolar Disorder and 25-mg Oral Tablets in Healthy Subjects
Actual Study Start Date : March 27, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A: Sequence 1

Titration Period:

All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.

Treatment Period:

Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15.

Drug: Seroquel IR 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation A 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation B 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Experimental: Part A: Sequence 2

Titration Period:

All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.

Treatment Period:

Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15.

Drug: Seroquel IR 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation A 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation B 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Experimental: Part A: Sequence 3

Titration Period:

All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.

Treatment Period:

Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15.

Drug: Seroquel IR 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation A 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Drug: Quetiapine Formulation B 300mg
Administered during Part A, administered orally BID with water, over 5 days.

Experimental: Part B: Sequence 1
Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
Drug: Seroquel IR 25mg
Administered during Part B, as a single, 25mg dose taken with water.

Drug: Quetiapine Formulation 25mg
Administered during Part B, as a single, 25mg dose taken with water.

Experimental: Part B: Sequence 2
Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
Drug: Seroquel IR 25mg
Administered during Part B, as a single, 25mg dose taken with water.

Drug: Quetiapine Formulation 25mg
Administered during Part B, as a single, 25mg dose taken with water.




Primary Outcome Measures :
  1. Part A: Maximum Observed Plasma Concentration (Cmax) for Quetiapine [ Time Frame: Pre-dose on days 4, 9 and 14, 12 hours post morning dose on Days 4, 9 and 14 and pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 3, 4, 6, 8, 10 and 12 hours post morning dose on days 5, 10 and 15 ]
    Pharmacokinetic endpoint analysis will be done separately for formulation A and formulation B.

  2. Part A: Area Under the Concentration-Time Curve Calculated to the Last Observable Concentration at Time t (AUCt) for Quetiapine [ Time Frame: Pre-dose on days 4, 9 and 14, 12 hours post morning dose on Days 4, 9 and 14 and pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 3, 4, 6, 8, 10 and 12 hours post morning dose on days 5, 10 and 15 ]
    Pharmacokinetic endpoint analysis will be done separately for formulation A and formulation B.

  3. Part B: Maximum Observed Plasma Concentration (Cmax) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]
  4. Part B: Area Under the Concentration-Time Curve Calculated to the Last Observable Concentration at Time t (AUCt) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]
  5. Part B: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC∞) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]

Secondary Outcome Measures :
  1. Part A: Time to Maximum (Peak) Plasma Concentration (tmax) for Quetiapine [ Time Frame: Pre-dose on days 4, 9 and 14, 12 hours post morning dose on Days 4, 9 and 14 and pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 3, 4, 6, 8, 10 and 12 hours post morning dose on days 5, 10 and 15 ]
    Pharmacokinetic endpoint analysis will be done separately for formulation A and formulation B.

  2. Part A: Terminal-Phase Elimination Half-Life (t1/2,z) for Quetiapine [ Time Frame: Pre-dose on days 4, 9 and 14, 12 hours post morning dose on Days 4, 9 and 14 and pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 3, 4, 6, 8, 10 and 12 hours post morning dose on days 5, 10 and 15 ]
    Pharmacokinetic endpoint analysis will be done separately for formulation A and formulation B.

  3. Part A: Apparent Clearance of Drug from Plasma After Extravascular Administration (CL/F) for Quetiapine [ Time Frame: Pre-dose on days 4, 9 and 14, 12 hours post morning dose on Days 4, 9 and 14 and pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 3, 4, 6, 8, 10 and 12 hours post morning dose on days 5, 10 and 15 ]
    Pharmacokinetic endpoint analysis will be done separately for formulation A and formulation B.

  4. Part A: Percentage of Participants who Experience at Least One Treatment-Emergent Adverse Event [ Time Frame: Day 1 to End of Follow-Up (Day 45[+/- 2 days]) ]
    An adverse event is defined as as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A Treatment-Emergent Adverse Event (TEAE) is defined as an adverse event that occurs after treatment has begun.

  5. Part A: Percentage of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs [ Time Frame: Baseline (Day -1) to Day 11 ]
    Vital signs will include blood pressure, heart rate, temperature, and respiratory rate.

  6. Part A: Percentage of Participants who Experience a Significant Change from Baseline in ECGs [ Time Frame: Baseline (Day -1) to Day 11 ]
    Standard 12-lead electrocardiograms will be used.

  7. Part A: Percentage of Participants who Experience a Significant Change from Baseline in Clinical Laboratory Tests [ Time Frame: Baseline (Day -1) to Day 15 ]
    Clinical laboratory tests will be conducted at scheduled time points during Part A and Part B, including hematology, urinalysis, serum chemistry, drug screen and additional tests.

  8. Part A: Change from Baseline in Columbia-Suicide Severity Rating Scale Score [ Time Frame: Baseline (Day -1) and Day 15 ]
    Suicidality will be monitored throughout the trial using the C-SSRS (Columbia-Suicide Severity Rating Scale). This scale consists of a baseline evaluation that assesses the lifetime experience of the subject with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last assessment.The Baseline/ Screening Version and the Since Last Visit version of the C-SSRS will be completed by trained trial site staff at each visit. A numerical score will correspond to one of ten categories relating to suicidal ideation and suicidal behavior. A higher score indicates a higher risk of suicidal behavior, but an answer of 'yes' to any question indicates some risk.

  9. Part B: Time to Maximum (Peak) Plasma Concentration (tmax) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]
  10. Part B: Terminal-Phase Elimination Half-Life (t1/2,z) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]
  11. Part B: Apparent Clearance of Drug from Plasma After Extravascular Administration (CL/F) for Quetiapine [ Time Frame: Predose (within 30 minutes prior to dosing), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12 (Days 1 to 4), 24, 36 (Days 2 and 5), and 48 (Days 3 and 6) hours post dose ]
  12. Part B: Percentage of Participants who Experience at Least One Treatment-Emergent Adverse Event [ Time Frame: Day 1 to End of Follow-Up (Day 34 [+ 2 Days]) ]
    An adverse event is defined as as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A Treatment-Emergent Adverse Event (TEAE) is defined as an adverse event that occurs after treatment has begun.

  13. Part B: Percentage of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs [ Time Frame: Baseline (Day -1) to Day 6 ]
  14. Part B: Percentage of Participants who Experience a Significant Change from Baseline in ECGs [ Time Frame: Baseline (Day -1) to Day 6 ]
    Standard 12-lead electrocardiograms will be used.

  15. Part B: Percentage of Participants who Experience a Significant Change from Baseline in Clinical Laboratory Tests [ Time Frame: Baseline (Day -1) to Day 6 ]
    Clinical laboratory tests will be conducted at scheduled time points during Part A and Part B, including hematology, urinalysis, serum chemistry, drug screen and additional tests.

  16. Part B: Change from Baseline in Columbia-Suicide Severity Rating Scale Score [ Time Frame: Baseline (Day -1) and Day 6 ]
    Suicidality will be monitored throughout the trial using the C-SSRS (Columbia-Suicide Severity Rating Scale). This scale consists of a baseline evaluation that assesses the lifetime experience of the subject with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last assessment.The Baseline/ Screening Version and the Since Last Visit version of the C-SSRS will be completed by trained trial site staff at each visit. A numerical score will correspond to one of ten categories relating to suicidal ideation and suicidal behavior. A higher score indicates a higher risk of suicidal behavior, but an answer of 'yes' to any question indicates some risk.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Part A:

  • Must have a current diagnosis of schizophrenia or bipolar disorder, as determined by the Diagnostic and Statistical Manual of Mental Disorders Version 5 (DSM-5) criteria.
  • Must have a Body Mass Index between 18 and 35 kg/m^2.
  • Good physical health as determined by no clinically significant deviation from normal, in the opinion of the investigator, in medical history, clinical laboratory determination, ECGs, or physical examinations.
  • Participants must be considered stable, per the investigator's judgment, on one of the following atypical oral antipsychotic medications at an adequate dose (eg, low- to mid-range of the recommended dose range for the treatment of schizophrenia or bipolar disorder, according to the manufacturer labeling) and for an adequate duration (30 days) prior to the administration of IMP: aripiprazole, brexpiprazole, risperidone, olanzapine, quetiapine, ziprasidone, paliperidone, cariprazine, lurasidone, and asenapine. Other oral antipsychotic medications may be allowed if approved by the medical monitor and sponsor; however, clozapine will not be allowed. Per the investigator's judgment, they should be comfortable with the participant discontinuing background antipsychotic therapy during the trial period and then restarting the antipsychotic therapy once trial participation has been completed.

Part B:

  • Male or female participants between 18 and 45 years of age, inclusive.
  • Must have a Body Mass Index between 18 and 32 kg/m^2.
  • Good physical health as determined by no clinically significant deviation from normal, in the opinion of the investigator, in medical history, clinical laboratory determination, ECGs, or physical examinations.
  • Able to provide informed consent prior to the initiation of any protocol-related procedures.
  • Male and female participants who are surgically sterile, female participants who have been postmenopausal for at least 12 consecutive months prior to the screening visit, or male participants/female participants (of childbearing potential) who agree to practice 2 of the approved birth control methods from the screening visit and for at least 30 days after the last dose of IMP for a female participant or 80 days after the last dose of IMP for a male participant.

Exclusion Criteria:

Part A:

  • Participants who are unable to stop receiving varenicline beyond the screening visit. If a participant is receiving varenicline at the screening visit, attempts should be made to discontinue the medication, if clinically feasible, to allow potential participants to enter the trial.
  • Participants who have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on questions 4 or 5 (current or over the last 3 months) on the Baseline/Screening Version of the C-SSRS or participants with any suicidal behavior during the 6 months prior to the screening visit.
  • Participants currently in an acute relapse of schizophrenia as assessed by the investigator. Bipolar participants who currently have an unstable mood (manic, mixed, or depressed) as assessed by the investigator.
  • Participants with a current DSM-5 diagnosis other than schizophrenia or bipolar disorder, including schizoaffective disorder, major depressive disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, participants with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Use of any moderate-strong CYP3A4 inhibitor or inducer within 14 days or 5 plasma half-lives (whichever is longer) prior to the administration of IMP and for the duration of the trial. Weak CYP3A4 inhibitors, including valproic acid, may be allowed based on the investigator's judgment, provided the participant has been on a stable dose for at least 30 days prior to IMP administration and throughout the duration of the trial.
  • Participants with a history of neuroleptic malignant syndrome, seizure disorder, or clinically significant tardive dyskinesia as assessed by the investigator.
  • Subjects with a history of any significant drug allergy or known or suspected hypersensitivity to antipsychotics, in particular to quetiapine.
  • Participants who are maintained on long-acting insulin.
  • Any participant who does not successfully tolerate a quetiapine dose of 300 mg BID during the titration period of this trial.

Part B:

  • History of any significant drug allergy to quetiapine, prescription drugs, non-prescription drugs, or food.
  • Any history of significant bleeding or hemorrhagic tendencies.
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to screening through the end of the trial (eg, occupational exposure to pesticides, organic solvents, etc).
  • Participants who have supine blood pressure after resting for ≥ 5 minutes, higher than 130/80 mmHg or lower than 100/50 mmHg (systolic/diastolic). The sponsor may allow exceptions if they are not deemed clinically significant.
  • Participants who have a supine pulse rate, after resting for ≥ 5 minutes, outside the range of 60 to 90 beats per minute. The sponsor may allow exceptions if they are not deemed clinically significant (eg, bradycardia attributable to superior physical fitness).
  • History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.
  • Use of any CYP3A4 inhibitors or CYP3A4 inducers within 14 days or 5 plasma half-lives (whichever is longer) prior to the administration of IMP and for the duration of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03872596


Contacts
Layout table for location contacts
Contact: Javier Ache 619-293-6206 achejavier@prahs.com

Locations
Layout table for location information
United States, California
Collaborative Neurosciences Network, LLC Recruiting
Long Beach, California, United States, 90806
Contact: David Walling, Dr         
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
PRA Health Sciences
Investigators
Layout table for investigator information
Study Director: Ernest Roos, M.D. Otsuka Pharmaceutical Development & Commercialization, Inc.

Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT03872596     History of Changes
Other Study ID Numbers: 304-201-00001
First Posted: March 13, 2019    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Seroquel
Digital Medicine Quetiapine
Pharmacokinetics
Bioavailability
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Schizophrenia
Bipolar Disorder
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Bipolar and Related Disorders
Quetiapine Fumarate
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs